Montelukast for Children From 6 To 14 Years Accord Healthcare

Montelukast, the active ingredient in Montelukast for Children From 6 To 14 Years Accord Healthcare, is a leukotriene receptor antagonist presented as an oral dosage form for oral use. It treats asthma and allergic rhinitis in children aged 6–14 years.

GNH USA supplies Montelukast for Children From 6 To 14 Years Accord Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast is used to manage conditions that involve leukotriene‑mediated airway inflammation and nasal symptoms. - Asthma: improves control of persistent asthma and reduces the frequency of exacerbations in children. - Allergic rhinitis: relieves nasal congestion, sneezing and itching associated with seasonal or perennial allergic rhinitis. - Exercise‑induced bronchoconstriction: prevents airway narrowing that occurs during or after physical activity.

Montelukast may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate pain often reported during the first weeks of therapy. - Abdominal pain: intermittent discomfort or cramping in the stomach region. - Cough: non‑productive cough without signs of infection. - Nausea: feeling of queasiness that may resolve without intervention.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema or anaphylaxis requiring immediate medical attention. - Neuropsychiatric events: mood changes, agitation, or suicidal thoughts, especially in adolescents. - Hepatic enzyme elevation: abnormal liver function tests that may need monitoring.

Before initiating Montelukast, consider the following safety measures. - Neuropsychiatric monitoring: observe for mood changes, anxiety or suicidal ideation, particularly in adolescents. - Hepatic function: assess baseline liver enzymes in patients with known liver disease. - Severe asthma: do not replace rescue inhalers; continue short‑acting bronchodilators as needed. - Hypersensitivity: avoid use in individuals with documented allergy to Montelukast or any excipients. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Montelukast may interact with other medicines that affect its metabolism or pharmacodynamic profile.

Major Interactions (Avoid): - Phenobarbital: induces hepatic enzymes, reducing Montelukast plasma levels. - Rifampin: strong enzyme inducer that may diminish therapeutic effect. - Ketoconazole: potent CYP3A4 inhibitor that can increase Montelukast exposure.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of anticoagulant effect; monitor INR. - Theophylline: may experience altered bronchodilator response; observe clinical response.